Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved by the FDA for the treatment of type 2 diabetes (under the brand names Ozempic and Rybelsus) and chronic weight management (as Wegovy)
Benchmarking against SUSTAIN-6 and SURPASS-CVOT In the emulation of SUSTAIN-6 comparing semaglutide to sitagliptin, a proxy for placebo, in patients at moderate and high cardiovascular risk (Table 2 and Supplementary Table 19), the hazard ratio (HR) for the primary endpoint was 0.68 (95% confidence interval (CI) 0.600.77) compared to the trial estimate of HR 0.74 (95% CI 0.58 to 0.95)
As an injectable GLP-1 receptor agonist, Wegovy represents a new class of weight loss treatments
One well-known example: sildenafil, which you probably know as Viagra
How Fast Does Semaglutide Work for Weight Loss
Consistent with this idea, semaglutide-mediated enhancement of energy expenditure has been described in obese mice [48]